Inside informationEnglish
Press Release: Sanofi’s amlitelimab met all primary and key secondary endpoints in the COAST 1 phase 3 study in adults and adolescents with atopic dermatitis
The file is served by the AMF. We do not host a copy.
Document type
- Issuer
- Sanofi
- Filed
- 04/09/2025, 07:01
- Document type
- Inside information
- AMF sub-type
- Informations privilégiées
- Language
- English
- AMF reference
- 116233_20250904